Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Agios Pharmaceuticals (AGIO) Leases (2019 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Leases for 8 consecutive years, with $27.2 million as the latest value for Q1 2026.

  • For Q1 2026, Leases fell 31.77% year-over-year to $27.2 million; the TTM value through Mar 2026 reached $27.2 million, down 31.77%, while the annual FY2025 figure was $30.5 million, 28.98% down from the prior year.
  • Leases hit $27.2 million in Q1 2026 for Agios Pharmaceuticals, down from $30.5 million in the prior quarter.
  • Across five years, Leases topped out at $65.1 million in Q4 2022 and bottomed at $64000.0 in Q2 2022.
  • Average Leases over 5 years is $41.0 million, with a median of $44.4 million recorded in 2024.
  • Year-over-year, Leases plummeted 99.88% in 2022 and then skyrocketed 93440.62% in 2023.
  • Agios Pharmaceuticals' Leases stood at $65.1 million in 2022, then fell by 16.46% to $54.4 million in 2023, then dropped by 21.19% to $42.9 million in 2024, then fell by 28.98% to $30.5 million in 2025, then fell by 10.7% to $27.2 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $27.2 million, $30.5 million, and $33.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.